SCHEMBL3316864

SCHEMBL3316864

CCC(CC)C(O)c1ccnn1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.39
MAPT P10636 2/20 0.35
MLYCD O95822 2/20 0.35
SCN9A Q15858 1/20 0.35
CHRNA7 P36544 1/20 0.35
PDE2A O00408 2/20 0.35
ATM Q13315 1/20 0.34
CASR P41180 1/20 0.34
RAB9A P51151 1/20 0.34
CTDSP1 Q9GZU7 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HRH3 Q9Y5N1 2/20 0.34
NPBWR1 P48145 2/20 0.34
CYP2C9 P11712 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDM5A P29375 1/20 0.34
KDM4C Q9H3R0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3318294 0.84 HIF1A (0.41) HIF1AMAPTCHRNA7ATMCASR
SCHEMBL3319046 0.83 POLB (0.43) HIF1ACYP2C9
SCHEMBL3316855 0.80 NPBWR1 (0.40) HIF1AMAPTRAB9ANPBWR1CYP2C9
SCHEMBL20001726 0.70 HIF1A (0.41) HIF1AMAPTATMRAB9ACTDSP1
SCHEMBL31466271 0.70 OXTR (0.44) HIF1AMAPTATMRAB9ACTDSP1
SCHEMBL3319315 0.68 NR3C1 (0.38) L3MBTL1KDM5AKDM4C
SCHEMBL24214812 0.66 HIF1A (0.41) HIF1AMAPTATMRAB9ACTDSP1
SCHEMBL28878347 0.66 POLB (0.58) HIF1AMAPTATMRAB9ACTDSP1
SCHEMBL15638806 0.66 MGLL (0.44) HIF1AMAPTATMRAB9ACTDSP1
SCHEMBL3320565 0.66 ALDH1A1 (0.38) HIF1AMAPTATMRAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144812-A1 Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production Containing an Azole WYETH LLP (US) 2010-06-10 US disclosed
US-7674813-B2 Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole WYETH (US) 2010-03-09 US disclosed
EP-1709003-B1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH CORP (US) 2009-09-23 EP disclosed
US-20080249150-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH (US) 2008-10-09 US disclosed
US-7399778-B2 Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole WYETH (US) 2008-07-15 US disclosed
EP-1709003-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE Wyeth (US) 2006-10-11 EP disclosed
WO-2005073198-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH (US) 2005-08-11 WO disclosed
US-20050171180-A1 Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole WYETH (US) 2005-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144812-A1 Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production Containing an Azole APP, IAPP, PARK7 HIF1A 3064/4885MAPT 524/4885MLYCD 3756/4885
US-20080249150-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE APP, IAPP, PARK7 HIF1A 3064/4885MAPT 524/4885MLYCD 3756/4885
US-20050171180-A1 Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole IAPP, APP, CBR3 HIF1A 2753/4885MAPT 1135/4885MLYCD 4096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.